EcoDrugPlus

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSOKIG00005032922
Gene Symbol: CHRM5B
1 Cross references
184 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSOKIG00005023088
Gene Symbol: CHRNA4B
1 Cross references
191 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSOKIG00005039736
Gene Symbol: CHRNA7A
1 Cross references
204 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSOKIG00005018463
Gene Symbol: F2R
3 Cross references
257 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSOKIG00005049246
Gene Symbol: F2R
3 Cross references
257 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSOKIG00005049298
Gene Symbol: F3
1 Cross references
172 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSOKIG00005017006
Gene Symbol: F10
1 Cross references
235 Possible Orthologues:

Coiled-Coil Domain-Containing Protein 6

Ensembl ID : ENSOKIG00005033663
Gene Symbol: LOC109899759
3 Cross references
201 Possible Orthologues:

Coiled-Coil Domain-Containing Protein 6-Like

Ensembl ID : ENSOKIG00005044385
Gene Symbol: LOC109890000
3 Cross references
201 Possible Orthologues:

Collagenase 3

Ensembl ID : ENSOKIG00005028464
Gene Symbol: LOC109872935
2 Cross references
301 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSOKIG00005009515
Gene Symbol: LOC109892118
2 Cross references
301 Possible Orthologues:

Colony Stimulating Factor 1 Receptor

Ensembl ID : ENSOKIG00005038265
Gene Symbol: CSF1R
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).